Zhenquan Hu

PostDoc

350 Shushanhu Road, Hefei, Anhui, 230031, P.R. China

Tel:+86-551-65591485

Email: zhqhu@hmfl.ac.cn

Research interest

  1. Molecular Modeling, programming
  2. Computational-aided drug design

Education background

2012/02-2015/09, PhD, Pharmaceutical Sciences, University of Basel, Switzerland
2008/09-2011/06, MS, Organic Chemistry, Shanghai Institute of Organic Chemistry, CAS
2002/09-2006/06, BS, Applied Chemistry, Wuhan University

Research Experience

2018/02-present, Assistant Professor, High Magnetic Field Laboratory, CAS
2015/10-2018-01, PostDoc, High Magnetic Field Laboratory, CAS
2011/08-2012.01, Research Associate, Shanghai Institute of Organic Chemistry
2006/07-2007/07, Research Associate, ChemPartner Co. Ltd., Shanghai

PUBLICATONS

  1. Zhenquan Hu#, Jo？l Wahl, Matthias Hamburger, Angelo Vedani*. Molecular mechanisms of endocrine and metabolic disruption: An in silico study on antitrypanosomal natural products and some derivatives. Toxicol. Lett. 2016, 252: 29-41. doi: 10.1016/j.toxlet.2016.04.013.
  2. Angelo Vedani*, Max Dobler, Zhenquan Hu, Martin Smie？ko. OpenVirtualToxLab—A platform for generating and exchanging in silico toxicity data. Toxicol. Lett. 2015, 232(2): 519–532. doi: 10.1016/j.toxlet.2014.09.004.
  3. Shuguang Yuan*, H.C. Stephan Chan, Zhenquan Hu. Using PyMOL as a platform for computational drug design. WIREs Comput. Mol. Sci. 2017, e1298. doi: 10.1002/wcms.1298.
  4. Shuguang Yuan*, Zhenquan Hu, Slawomir Filipek, Horst Vogel*. W246(6.48) Opens a Gate for a Continuous Intrinsic Water Pathway during Activation of the Adenosine？A2A Receptor. Angew. Chem. Int. Ed. 2015, 54(2): 556-559. doi: 10.1002/anie.201409679.
  5. Qianmao Liang#, Yongfei Chen#, Kailin Yu#, Cheng Chen#, Shouxiang Zhang, Aoli Wang, Wei Wang, Hong Wu, Xiaochuan Liu, Beilei Wang, Li Wang, Zhenquan Hu, Wenchao Wang, Tao Ren, Shanchun Zhang, Qingsong Liu*, Cai-Hong Yun*, Jing Liu*. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. Eur. J. Med. Chem. 2017, 131: 107-125. doi: 10.1016/j.ejmech.2017.03.001.
  6. Xiaofei Liang#, Fengchao Lv#, Beilei Wang#, Kailin Yu#, Hong Wu, Ziping Qi, Zongru Jiang, Cheng Chen, Aoli Wang, Weili Miao, Wenchao Wang, Zhenquan Hu, Juan Liu, Xiaochuan Liu, Zheng Zhao, Li Wang, Shanchun Zhang, Zi Ye, Chu Wang, Tao Ren, Yinsheng Wang, Qingsong Liu*, and Jing Liu*. Discovery of 2-((3-acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. J. Med. Chem. 2017, 60(5):1793-1816. doi:？10.1021/acs.jmedchem.6b01413.
  7. Xiaofei Liang#, Xiaochuan Liu#, Beilei Wang#, Fengming Zou#, Aoli Wang, Shuang Qi, Cheng Chen, Zheng Zhao, Wenchao Wang, Ziping Qi, Fengchao Lv, Zhenquan Hu, Li Wang, Shanchun Zhang, Qingsong Liu*, and Jing Liu*. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)-phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.J. Med. Chem. 2016, 59(5): 1984–2004. doi: 10.1021/acs.jmedchem.5b01618.
  8. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*, Jing Liu*. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J. Med. Chem. 2017, 60(1): 273-289. doi: 10.1021/acs.jmedchem.6b01290.
  9. Binhua Li#, Aoli Wang#, Juan Liu#, Ziping Qi#, Xiaochuan Liu#, Kailin Yu, Hong Wu, Cheng Chen, Chen Hu, Wenchao Wang, Jiaxin Wu, Zhenquan Hu, Ling Ye, Fengming Zou, Feiyang Liu, Beilei Wang, Li Wang, Tao Ren, Shaojuan Zhang, Mingfeng Bai, Shanchun Zhang, Jing Liu*, Qingsong Liu*. Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I “Gatekeeper” Mutant of cKIT Kinase. J. Med. Chem. 2016, 59(18): 8456-8472. doi: 10.1021/acs.jmedchem.6b00902.
  10. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Cheng Chen#, Xiaochuan Liu, Aoli Wang, Shuang Qi, Wenchao Wang, Ziping Qi, Zheng Zhao, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Yuexiang Wang, Jing Liu*, Qingsong Liu*. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med. Chem. 2016, 59(8): 3964-3979. doi: 10.1021/acs.jmedchem.6b00200.
  11. Xiaofei Liang#, Xiaochuan Liu#, Beilei Wang#, Fengming Zou#, Aoli Wang, Shuang Qi, Cheng Chen, Zheng Zhao, Wenchao Wang, Ziping Qi, Fengchao Lv, Zhenquan Hu, Li Wang, Shanchun Zhang, Qingsong Liu*, and Jing Liu*. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia. J. Med. Chem. 2016, 59(5): 1984-2004. doi: 10.1021/acs.jmedchem.5b01618.
  12. Feiyang Liu,# Beilei Wang,# Qiang Wang,# Ziping Qi,# Cheng Chen,# Lu-Lu Kong,# Ji-Yun Chen, Xiaochuan Liu, Aoli Wang, Chen Hu, Wenchao Wang, Huiping Wang, Fan Wu, Yanjie Ruan, Shuang Qi, Juan Liu, Fengming Zou, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Cai-Hong Yun*, Zhimin Zhai*, Jing Liu*, Qingsong Liu*. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Oncotarget 2016, 7(29): 45562-45574. doi: 10.18632/oncotarget.10037.